Leah Lawrence

Leah Lawrence is a freelance health writer and editor based in Delaware. She has contributed to trade, consumer, and medical association publications and websites focused on hematology/oncology, cardiology, primary care, endocrinology, and general health.

All articles by Leah Lawrence

$FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.$

Multiple Myeloma

Nomogram Shows Effect of Pleural Effusion on Myeloma Outcome

Leah Lawrence

April 16, 2021

A team of investigators report on their validated nomogram that incorporates pleural effusion into the classification of disease severity in patients with multiple myeloma.

$The management of metastatic breast cancer resistant or refractory to hormonal treatments, while sti$

Breast Cancer

Unplanned Implant Removal Following Treatment for Locally Advanced Breast Cancer

Leah Lawrence

April 15, 2021

A team of investigators assessed the frequency and timing of unplanned breast implant removal in patients undergoing with mastectomy, reconstruction, and postmastectomy radiation therapy for locally advanced breast cancer.

Multiple Myeloma

Prophylactic IVIG Is More Effective in Subgroups of Myeloma

Leah Lawrence

April 14, 2021

A retrospective, single-center crossover study was conducted that compared rates of infection in patients with multiple myeloma during observation compared with those receiving IVIG.

While survival rates of pediatric patients with cancer are greatly improved, researchers and clinici

Pediatric Cancer

Risk Factors for Pediatric Hemorrhagic Cystitis Following HCT

Leah Lawrence

April 14, 2021

Investigators conducted a study to determine the incidence and clinical course of BK virus hemorrhagic cystitis in children undergoing hematopoietic cell transplantation.

Gastrointestinal cancers have a diverse landscape of clinically relevant genomic alterations that co

Hematologic Cancers

Genome Sequencing: An Alternative for Risk Stratification in Myeloid Cancers

Leah Lawrence

April 13, 2021

A team of investigators assessed the application of whole-genome sequencing for genomic profiling of patients with acute myeloid leukemia or myelodysplastic syndromes.

This study led to the first clinical trial in humans to test trabectedin for CLL.

Chronic Lymphocytic Leukemia

Anti-CD20 Antibody Improved Response to Ibrutinib in High-Risk R/R CLL

Leah Lawrence

April 1, 2021

Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.

Whether cryosurgery or cryoablation will prove a viable alternative to lumpectomy — the standard of

Head and Neck Cancer

Endoscopic Surgery Improved OS for Locally Recurrent Nasopharyngeal Cancer

Leah Lawrence

March 31, 2021

A team of investigators conducted a randomized controlled trial to assess outcomes following salvage endoscopic surgery vs radiation therapy in patients with resectable, locally recurrent nasopharyngeal cancer.

Lymphoma

Low-Dose Aspirin Associated With Reduced Likelihood of Non-Hodgkin Lymphoma Diagnosis

Leah Lawrence

March 31, 2021

Investigators assessed the association of aspirin, other nonsteroidal anti-inflammatory drugs, and statins with the risk of developing non-Hodgkin lymphoma.

Circulating tumor DNA conveyed prognosis among patients with high-risk stage III melanoma, reinforcing the need to include this measure in clinical trial design.

Skin Cancer

Blood Cell Score for Identifying Aggressive Melanoma

Leah Lawrence

March 30, 2021

A team of investigators created the myeloid index score, which captures the prognostic value of blood myeloid cells and may be used in the management of patients with melanoma.

Analysis from phase II ENDEAVOR trial showed Kyprolis and dexamethasone superior to Velcade and dexa

Multiple Myeloma

Pharmacy-Based VTE Screening Mitigated Risk in Myeloma Patients

Leah Lawrence

March 23, 2021

A team of investigators sought to improve the rates of anticoagulation for high-risk patients after a quality improvement project that added pharmacy/hematology oversight to VTE risk assessment.

Next post in Multiple Myeloma